Comparison 2. Adjuvant.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Adverse events	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 Febrile neutropenia	5	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.24, 2.05]
1.2 Neutropenia	5	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.40, 0.97]
1.3 Neurotoxicity	3	162	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.25, 2.46]
1.4 Treatment‐related death	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Treatment adherence: delay in treatment	4	238	Risk Ratio (M‐H, Fixed, 95% CI)	0.76 [0.52, 1.12]
3 Treatment adherence: dose reduction	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 Taxane (docetaxel)	3	173	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.15, 0.73]
3.2 Anthracycline combination	2	117	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.18, 5.44]
4 Treatment adherence: one‐dose reduction	1	65	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.14, 2.10]
5 Treatment adherence: did not receive planned cycles	3	163	Risk Ratio (M‐H, Fixed, 95% CI)	0.45 [0.15, 1.31]